Because of dementia's prolonged disease course, advance care decisions and planning are often overlooked until it is too late.
There are currently no treatments available for frontotemporal dementia.
Positron emission tomographic imaging can directly measure synaptic loss with Alzheimer disease.
The findings suggest that confabulations by patients with AD are related to an impaired ability to mentally go back in time to retrieve the context in which the confabulated memories were encoded.
Lower cognitive ability total and verbal ability scores were predictive of greater risk for early-onset dementia.
Currently, there are no approved treatments for behavioral symptoms in Alzheimer disease.
Investigators reviewed data from patients aged 45 to 64 years who were enrolled in the Atherosclerosis Risk in Communities Study and who attended additional visits for cognitive function evaluation and repeat cardiovascular risk factor assessment.
An international team of investigators assessed the ability of flutemetamol F 18-labeled PET and other biomarkers to predict risk of clinical progression from amnestic mild cognitive impairment to probable Alzheimer disease.
Investigators sought to assess factors contributing to progression of functional, cognitive, and motor impairment in Huntington disease.
In patients with and without dementia, amyloid-positive and negative results were significantly linked to diagnoses and treatment changes.
For an unselected memory clinic cohort, amyloid PET results are associated with changes in etiology, diagnostic confidence, and patient treatment.
While hundreds of published reports have made an argument for an association between Alzheimer disease and bacteria and viruses, the suggestion of a viral contribution to Alzheimer disease has not always been well received by the greater research community.
Decision tree and random forest classification models were used to find associations between patient demographic and lifestyle risk factors with dementia status during more than 30 years of follow-up.
Measurement of the disease protein huntingtin in saliva may be promising as an accessible, noninvasive biomarker to predict symptom severity and disease course in individuals with Huntington disease.
Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.
The risk of dementia is increased in 50-year-olds with blood pressure ≥130 mm Hg, which is below the current threshold for hypertension.
Active participation in intellectual activities among adults aged 65 years or older is associated with reduced risk of dementia.
Using the Visual Association Test along with the Mini Mental State Examination may improve predictive value to screen for cognitive deficits.
The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.
In the discovery stage, genome-wide and logistic and linear regression analyses were performed to examine the association of genetic variants with risk for disease and age at onset in those with a GRN mutation and controls who were free of neurodegenerative disorders.
The investigators analyzed specific AD biomarkers, including β-amyloid 42, total tau, and phosphorylated tau measured in CSF.
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- High Treatment Adherence and Quality of Life Observed With Fingolimod
- Gender Differences in the Epidemiology of Migraine
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Insurance Status Tied to Higher Self-Perceived Poor/Fair Health
- Early Treatment Failure More Likely With Carbamazepine vs Lamotrigine in Epilepsy
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Concurrent Non-Motor Functions Strongly Associated With Parkinson Disease
- Feeling Young May Be Reflected in Brain Structure